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1. BRIEF BACKGROUND 
 
1.1 Trial overview 
Mastitis and accompanying pain have been associated with the cessation of breastfeeding.1-3 Mastitis 
is an inflammatory condition of the breast and may be related to decreased immunity and lowered 
resistance to infection. 4 Mastitis affects up to one in five breastfeeding women with most episodes 
occurring in the first 6-8 weeks postpartum.5 Antibiotics are often used in the treatment of mastitis, 
but have not been popular or proven effective as a preventative agent.6 The WHO has highlighted 
significant concerns relating to adverse harms of antibiotic use with the production of antibiotic-
resistant strains of disease organisms.7 Increasing research suggests that specific probiotic bacteria 
possess significant anti-inflammatory properties and supports their potential use as 
immunomodulatory agents.8 While animal studies have shown promising results in the use of 
probiotics for preventing mastitis9, their use in human trials has had limited investigation. 
 
APProve is a double-blind randomised controlled trial assessing outcomes between breastfeeding 
women ingesting a probiotic versus a placebo daily for 8 weeks following birth. The protocol for the 
trial was published in 2017.10 Ethics approval has been given by the Northern Sydney Local Health 
District Human Research Ethics Committee: HREC/14/HAWKE/358. The trial is registered with the 
Australian New Zealand Clinical Trials Registry: ACTRN12615000923561. Grant funding was 
obtained from the The Ramsay Research and Teaching Fund (The Kolling Institute: Northern Sydney 
Local Health District and the University of Sydney, Sydney Medical School).   Eligible women are 
randomised by a computer random number generator to either probiotic or placebo, stratified by 
previous mastitis. Trial outcomes are being collected using a mobile phone application system 
(APProve-Lite), with a sub-set of women using ‘standard’ data collection by means of a calendar 
diary and weekly emails.  
 
1.2 Trial timeline 
 
16/04/2015  First participant recruited to the trial
19/09/2016  Data Monitoring Committee review of trial progress and safety. Determination made that 
trial should continue. 
01/12/2016     Final participant recruited
30/05/2017              Follow‐up: primary outcome completed / analysis commenced
End of 2017              Dataset locked; treatment assignment unblinded 
March 2018              Follow‐up: secondary outcomes completed / analysis commenced 
mid 2018                  Reporting and dissemination of trial outcomes
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1.3 Aims 
The primary aim of this study is to evaluate the effectiveness of the oral probiotic Lactobacillus 
Fermentum for the prevention of mastitis in breastfeeding women.  
 
Secondary aims will assess maternal breastfeeding outcomes, overall maternal and infant health and 
well-being, maternal lifestyle factors which may affect breastfeeding outcomes, acceptability and 
compliance of the trial product and the APProve-Lite system, and preference for method of post-natal 
questionnaires. 
 
1.4 Study design   
This is a double-blind randomised controlled trial assessing the outcomes between breastfeeding 
women ingesting a probiotic versus a placebo. Randomisation to either “probiotic” or “placebo” will 
take place immediately after consent within 72 hours of delivery. A computer random number 
generator will be used to prepare the randomisation schedule in blocks of 4 and 6, and stratified by the 
incidence of previous mastitis. The randomisation sequence will be concealed until all data has been 
collected. The participant and researcher will be blinded as to treatment allocation. Participants using 
APProve-Lite will be randomised via a central password-protected web-based application. 
Concealment for participants using the “standard‟ approach (not the APProve-Lite system) will be via 
opaque, sealed envelopes. 
 
1.5 Eligibility criteria 
Inclusion criteria: Women ≥18 years of age who have delivered a singleton baby at 37 weeks 
gestation or later will be invited to participate in the trial. They will currently not be taking 
commercial probiotics containing lactobacillus fermentum; and will own a smartphone. Their 
intention at the time of consent will be to breastfeed their baby.  
 
Exclusion criteria: Women with a history of Raynaud syndrome will not be eligible to participate in 
the trial. Any delivery/breast complication rendering the infant unable to breastfeed will be excluded. 
Women unable to speak/understand English will not be consented. 
 
1.6 Intervention 
The participant will be given an eight-week supply of her allocated treatment.  The probiotic sachets 
and placebo sachets will be identical in every respect except for the Lactobacillus Fermentum 
CECT5716 (NLT 3x109 cfu/g) ingredient contained in the probiotic. Participants will be advised to 
take one sachet daily for a period of eight weeks following the birth of her baby and to refrigerate the 
boxes of sachets at home. The contents of the sachet should be mixed with water, juice or milk, stirred 
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and consumed immediately. Women will be advised not to make up for missed doses by double-
dosing, but rather to continue their daily routine as soon as possible. The number of unused sachets 
will be collected by the research coordinator at the end of the eight week period.  
 
Participants will be encouraged to maintain routine health care. If antibiotics are prescribed, women 
will be encouraged to continue with their treatment regime, but advised to take the treatment sachet at 
least two hours after taking the antibiotic.  
 
1.7 Data collection and follow up  
Trial data was collected at each of the following time points using the following forms: 
Form used  Data collected Timing 
Trial Entry Form  Baseline maternal demographic and medical information At randomisation
Discharge Form  Data related to the birth and infant feeding At discharge 
Daily Postnatal 
Questionnaire / 
Calendar Diary 
Data collection of treatment compliance, breast pain, 
infection symptoms and infant feeding  Daily x 56 
Weekly Postnatal 
Questionnaire 
Data collection of well‐being, Drs’ visits, and  
medication intake  Weekly x 8 
Postnatal 
Questionnaire 
 
Data collection of trial compliance and satisfaction (2 
months only), general maternal and infant health and 
well‐being, maternal/infant feeding practices, and 
maternal lifestyle factors. 
2, 6 and 12 months 
postpartum 
 
 
1.8 Trial endpoints 
1.8.1 Primary outcome: mastitis 
The primary outcome will be defined as the incidence of mastitis up to eight weeks following delivery 
as measured by:  
1) Clinical diagnosis of mastitis OR 
2) At least two of the following breast symptoms: breast pain*, redness/inflammation, lump/swelling 
AND at least one of the following systemic symptoms: flu-like symptoms (body aches, headaches 
and chills) or fever ≥38 degrees Celsius. These symptoms must be present for at least 24 hours.11  
*Breast pain will be defined as an increase from the individual’s median breast pain score. 
 
Mastitis will be analysed as a dichotomous outcome as obtained from survey responses (including 
free text responses and personal contact) to: 
a. The daily postnatal questionnaire or calendar diary which fulfil the criteria of clinical 
symptoms (see above) at least 2 days in a row. 
b. The weekly postnatal questionnaire.  
c. The 2-month follow-up questionnaire. 
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1.8.2 Secondary maternal and pregnancy outcomes  
 Secondary outcomes will be analysed on women for whom 2-month follow-up data has been 
obtained. Data sources will include all responses (including free text and personal contact) obtained 
from the daily postnatal questionnaire or calendar diary, the weekly postnatal questionnaire, and the 
2-month questionnaire. 
 
1.8.2a Trial treatment 
1. Treatment compliance will be analysed as a dichotomous variable.  
Treatment compliance will be categorised into: 
 Compliant: defined as having consumed the product for 42 days or more. 
 Semi-compliant: defined as having consumed the product for 15-41 days. 
 Non-compliant: defined as having consumed the product for 14 days or less. 
2. Self- reported side effects will be analysed as a dichotomous variable and a thematic outcome.  
3. Ease of taking the trial treatment will be analysed as a categorical variable. 
 
1.8.2b Breastfeeding  
4. Breastfeeding status and length of time breastfeeding will be analysed both as a continuous 
and categorical variable.  
5. Reasons for discontinuing breastfeeding will be analysed as a thematic outcome. 
6. Oversupply of milk will be analysed as a dichotomous variable. 
7. Cracked nipples will be analysed as a dichotomous variable. 
8. Use of nipple shields will be analysed as a dichotomous variable. 
 
1.8.2c Maternal health/lifestyle  
9. Maternal anxiety will be analysed using an interval scale based on the State Trait Anxiety 
Index (STAI-6) developed by Marteau and Bekker, 1992.12 Aggregated scores will be 
standardised to a range of 20-80, with 20 = low anxiety. Mean and standard deviation of 
scores will be determined and compared between the two study groups. 
10. Maternal physical and emotional health will be analysed using an interval scale based on the 
Short Form Health Survey (SF-12).13 The SF-12 includes 8 concepts commonly represented 
in health surveys: physical functioning, role functioning physical, bodily pain, general health, 
vitality, social functioning, role functioning emotional, and mental health. Results are 
expressed in terms of two meta-scores: the Physical Component Summary (PCS) and the 
Mental Component Summary (MCS). The PCS and MCS scores have a range of 0 to 100 and 
were designed to have a mean score of 50 and a standard deviation of 10. Thus, scores greater 
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than 50 indicate better physical or mental health than the mean and scores < 50 indicate worse 
health.  Scores will be determined based on: 
a. Reverse scoring of 4 items is required, so that a higher score is equivalent to better 
health. These include Q1, Q8, Q9, and Q10. 
b. SF12 score is missing if any one item is missing. 
c. An algorithm13 will be used to generate the physical and mental health composite 
scores based on responses to Q1-12.  
d. The mean difference between the PCS and MCS scores between the 2 study groups 
will then be compared suing t-tests.  
11. Infections (other than mastitis) will be analysed as a categorical variable.  
12. Doctor’s visits for health-related reason will be analysed as a categorical variable.  
13. Visits to other health professionals will be analysed as a categorical variable.  
 
1.8.3 Secondary infant outcomes  
1. Concerns about baby’s health will be analysed as a dichotomous variable. 
2. Adverse conditions will be analysed as a dichotomous variable. If numbers are sufficient, the 
type of symptoms reported will be summarised.   
3. Infections will be analysed as a categorical variable. If numbers are sufficient, the type of 
infections reported will be summarised. 
4. Allergies will be analysed as a dichotomous variable. If numbers are sufficient, the type of 
allergies reported will be summarised. 
5. Doctor’s visits for baby will be analysed as a dichotomous variable. If numbers are sufficient, 
the reported reasons for a doctor’s visit will be summarised. 
6. Infant hospitalisations will be analysed as a dichotomous variable. If numbers are sufficient, 
the reported reason for infant hospitalisation will be summarised 
7. Infant weight at 2 months will be analysed as a continuous variable. 
 
1.8.4 Sub-group analysis (for primary outcome only) 
1. Compliance – see 1.8.2a, section 1. 
2. Breastfeeding duration – see 1.8.2b. Will be measured at 1 month and at 2 months. 
3. Antibiotic administration during labour, at birth and postpartum prior to discharge will be 
analysed as a dichotomous variable.  
4. GBS positive during pregnancy and birth will be analysed as a dichotomous variable. 
5. The use of supplements during pregnancy and postpartum will be analysed as a categorical 
variable based on the following types: probiotics, vitamins, yoghurt, natural supplements, 
and none taken. 
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2. STATISTICAL ANALYSIS 
2.1 Sample size 
We chose a 50% reduction as a clinically meaningful treatment effect. Based on an expected rate of 
mastitis in the control group of 18%, two-sided 5% significance level and a power of 80%, we 
estimated a total sample size of 452 would be required. However, given studies related to the duration 
of breastfeeding report a cessation rate in the first eight weeks post-partum of up to 20%, and a 
potential loss-to follow-up of 5-10% may occur with withdrawals or non-compliance, we inflated the 
sample size by a further 30% to ensure complete data. Hence, we estimated a total sample size of 
approximately 600 women would be required (300 per group) for this trial. 
 
2.2 Participant flow diagram 
A CONSORT (Consolidated Standards of Reporting Trials) type diagram will be used to show the 
flow of participants into the final analysis. See Figure 1.  
 
2.3 Analysis Principles 
Analyses will be by intention-to-treat. The number of participants lost to follow-up will be reported. 
No participants will be excluded from the primary intention to treat analysis due to protocol 
violations.   
 
There will be an additional per-protocol analyses based on treatment compliance. Analyses will 
conform to Consolidated Standards of Reporting Trials (CONSORT) guidelines (http://www.consort-
statement.org/). 
 
Preliminary descriptive analyses of the frequency of randomisation and pre-randomisation 
characteristics using blinded trial data (does not include a treatment assignment field) will be 
performed. Un-blinding and analyses of trial outcomes will not be performed until the statistics plan is 
finalised. 
 
2.3.1 Distribution of baseline variables 
Maternal and pregnancy characteristics at or before randomisation, by trial arm, will be shown in 
Table 1 (see dummy table, page 12).  
 
2.3.2 Missing baseline variables 
There will be no imputation for missing values.  
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2.3.3 Missing primary outcome 
Only participants for whom the primary outcome is available will be included in the final analyses. 
Thus, there will be no imputation for missing values of the primary outcome. 
 
2.3.4 Unadjusted analysis of primary outcome 
Event numbers and percentages will be reported, by treatment arm as in dummy Table 4. Statistical 
significance will be two-sided at the P<0.05 level. Effect measures (relative risk) will be reported with 
a 95% confidence interval.  
 
2.3.5 Adjusted analysis of primary outcome 
A decision as to whether to perform adjusted analyses will NOT be determined by statistical testing of 
baseline differences between treatment arms, consistent with CONSORT recommendations 
(CONSORT Additional analyses, Item 12b). The randomisation process will be assessed by 
comparing the trial arms for clinically meaningful differences in parity, previous mastitis and site. 
 
If adjusted analyses are required per the above, a logistic regression model will be used. The 
covariates initially included as potential confounders will be: maternal age, country of birth, ethnicity, 
education, primary source of support, smoking/alcohol use during pregnancy, allergies, infections 
during pregnancy, antibiotics taken in month prior to birth, vitamins/supplements/probiotics taken in 
month prior to birth, previous pregnancies, previous viable births, previous breastfeeding 
(weeks/infant), previous mastitis (weeks postpartum/treatment), and time between birth and 
randomisation. (See Table 1)  
 
The pregnancy, birth and postpartum confounders will be: presentation at birth, labour onset, 
induction/augmentation, labour duration (minutes), method of delivery, use of analgesia, use of 
anaesthesia, antibiotics taken during labour, delivery and/or first week postpartum, GBS positive, 
breast-feeding commenced at birth, length of hospital stay (days), infant feeding at time of discharge. 
(See Table 2) 
 
Potential confounders related to infant details include: gestational age at birth, infant sex, Apgar 
scores at 5 minutes, resuscitation, to NICU/SCN and birth weight (grams).  (See Table 3) 
 
Backwards elimination will be used for factors which do not meet a statistical significance level of 
P=0.20, or alternatively to maintain a minimum events: covariates ratio of 10:1 in the model. Results 
will be reported as RR and 95% CI, as estimated from the model odds ratio and 95% CI. 
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2.3.6 Missing secondary outcomes 
There will be no imputation for missing values.  
 
2.3.7 Analysis of secondary outcomes 
Event numbers and percentages will be reported, by treatment arm. Dichotomous primary and 
secondary outcomes will be compared between treatment arms by calculating relative risks and 95% 
confidence intervals (RR, 95% CI), using the placebo as the comparison group. No adjustment to the 
level of statistical significance will be made for multiple comparisons. For normally distributed 
continuous data means between groups will be compared using a t-test, while for non-normally 
distributed data comparisons between groups will be performed using non-parametric Wilcoxon tests. 
If an adjusted analysis of the secondary outcomes is required, a similar analysis as per the “adjusted 
analysis of primary outcome” section above, will be conducted. 
 
2.3.8 A priori subgroup analyses 
The only pre-specified subgroup analyses will be for the primary outcome of mastitis and are shown 
in dummy Table 6: treatment compliance, breastfeeding duration measured at 4 weeks and at 8 weeks, 
antibiotic administration during labour, birth or postpartum prior to discharge, positive for GBS 
during pregnancy or birth, the use of supplements during pregnancy, the use of supplements 
postpartum, oversupply of milk, cracked nipples and the use of nipple shields.  Supplement use will 
be categorised as: probiotics, vitamins, yoghurt, natural supplements or none taken. 
 
2.3.9 Post-hoc hypotheses generating subgroup analyses 
Any post-hoc analyses (analyses not pre-specified in this SAP) which are completed to support the 
planned analyses will be clearly identified as such in any reporting of the trial.
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3. DUMMY TABLES 
Table 1: Maternal and pregnancy factors at or before time of randomisation 
 
 Probiotic 
n (%) 
Placebo 
 n (%) 
Maternal age (years) (mean) (SD)   
Country of birth   
Ethnicity   
Tertiary level education   
Primary source of support:  Partner      
Smoking in pregnancy   
Alcohol in pregnancy      
Infections during pregnancy   
Antibiotics in month prior to birth   
Supplements in month prior to birth 
     Probiotics 
     Vitamins 
     Yoghurt 
     Natural Supplements 
     None  
  
Allergies   
Number of pregnancies (median) (SD, range)   
First baby   
Previous breastfeeding   
Previous total breastfeeding weeks (mean) (SD*)   
Previous mastitis   
Time between birth and randomisation (days) (mean) (SD)   
Allocation per site 
     RNSH 
     RPAH 
     RHW 
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Table 2: Pregnancy, birth and postpartum details 
 Probiotic 
n (%) 
Placebo 
 n (%) 
Presentation: Cephalic 
                      Breech 
                      Other 
  
Labour onset: Spontaneous 
                       Induced (including ARM) 
                       No labour 
  
Induction/Augmentation   
Labour duration (minutes) (median) (SD, range)   
Method of delivery: Spontaneous vaginal 
                                Vacuum 
                                Forceps 
                                Emergency C/S 
                                Elective C/S 
  
Analgesia:   
Anaesthesia    
Antibiotics during labour/delivery   
GBS positive   
Antibiotics postpartum prior to discharge   
Breast-feeding commenced at birth (within 1 hour)   
Length of hospital stay (days) (mean, SD)   
Infant feeding at time of maternal discharge: 
          Exclusive (breast milk only) 
          Partial (breast milk and formula) 
  
 
 
 
 
 
Table 3: Infant details at delivery/discharge 
 
 Probiotic 
n (%) 
Placebo 
 n (%) 
Gestational age at birth (weeks) (mean, SD)   
Infant sex   
Apgar score at 5 minutes (mean, SD)   
Resuscitation   
To NICU/SCN   
Birth weight (grams) (mean, SD)   
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Table 4: Maternal Outcomes (2 months) 
 
 Probiotic 
n (%) 
Placebo 
 n (%) 
Relative risk 
RR (95% CI) 
Primary    
Mastitis    
    
Secondary     
Trial treatment:    
Compliance: Compliant 
                     Semi-compliant   
                     Non-compliant 
   
Self-reported side effects    
Ease of taking the treatment: (mean, SD)    
    
Breastfeeding factors:    
Breastfeeding at 8 weeks    
Oversupply of milk    
Cracked nipples    
Use of nipple shields    
    
Maternal health/lifestyle:    
Physical Health Composite Summary score (PCS, 
SF-12) (mean, SD) 
   
Mental Health Composite Summary score (MCS, 
SF-12) (mean, SD) 
   
Infections (other than mastitis)    
Dr visits for health-related reason    
Visit to other health professional    
 
 
Table 5: Infant outcomes (2 months) 
 
 Probiotic 
n (%) 
Placebo 
 n (%) 
Relative risk
RR (95% CI) 
Secondary    
Concerns about infant health    
Adverse infant conditions    
Infections    
Allergies    
Dr visits for health-related issue    
Hospitalisations    
Weight at 2 months (grams) (mean, SD)    
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Table 6: Pre-specified subgroup analyses for mastitis 
 
Maternal outcome Probiotic 
Mastitis 
n (%) 
Placebo 
Mastitis 
n (%) 
Mastitis 
RR (95% CI) 
Compliance  
     1 Compliant 
     2 Semi-compliant 
     3 Non-compliant 
   
Breastfeeding duration  
     1 At 4 weeks 
     2 At 8 weeks 
   
Antibiotic administration:  
     1 During labour 
     2 At birth 
     3 Postpartum prior to discharge 
   
GBS positive     
Use of supplements during pregnancy 
     1 Probiotics 
     2 Vitamins 
     3 Yoghurt 
     4 Natural supplements    
     5 None  
   
Use of supplements postpartum 
     1 Probiotics 
     2 Vitamins 
     3 Yoghurt 
     4 Natural supplements  
     5 None   
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Assessed for eligibility (n= ) 
Withdrawn after  
consent (n= ) 
Reasons 
Excluded (n= ) 
 Not meeting inclusion criteria (n= ) 
 Declined to participate (n= ) 
 Other reasons (n= ) 
Allocated to control (n= ) 
Withdrawn after  
consent (n= ) 
Reasons 
Enrolment 
Allocation 
Primary Outcome 
Secondary Outcomes 
Allocated to intervention (n= ) 
Figure 1: CONSORT Flow diagram for the APProve Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary outcome analysed 
(n= ) 
Lost to follow-up (n= ) 
Reasons 
Secondary outcomes 
analysed (n= ) 
Lost to follow-up (n= ) 
Reasons 
Randomized (n= ) 
Primary outcome analysed 
(n= ) 
Secondary outcomes 
analysed (n= ) 
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4. ADDITIONAL ANALYSES  
4.1 postpartum follow-up at 6 and 12 months 
Trial analyses also includes data collected at 6 months and 12 months postpartum and includes 
secondary outcomes relating to breastfeeding, maternal health and lifestyle, and infant health. Data 
collection for this part of the study will not be completed until the end February 2018. The results of 
these questionnaires will be analysed and reported separately from the main trial analysis.  
 
4.2 Analysis of Mobile Phone Application System 
A separate analysis will be undertaken comparing the trial outcomes between women whose data 
collection was via a specially designed Mobile Phone Application System (APP), and those women 
whose data collection was via a more conventional calendar diary and email (Non-APP).  Outcomes 
include ease of participation in the trial, ease of remembering to take the product, compliance with 
taking treatment and completing questionnaires, and recommendation for future studies. Qualitative 
data will analyse likes, dislikes and suggestions for future use of the two methods. This analysis will 
also ascertain preference for method of receiving questionnaires using only the APP data. The results 
of this component will be analysed and reported separately from the main trial analysis. 
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